Description: Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Home Page: www.clearmindmedicine.com
CMND Technical Analysis
1220 West 6th Avenue
Vancouver,
BC
V6H 1A5
Canada
Phone:
604 260 1566
Officers
| Name | Title |
|---|---|
| Prof. Mark Haden M.S.W. | Vice President of Business Development |
| Ms. Mylene Touboul | Accounting Manager |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7116 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-16 |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |